-
Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers
•
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its bevacizumab biosimilar. This biosimilar will be used to treat a range of cancers including metastatic colorectal cancer (CRC), recurrent glioblastoma, advanced metastatic or recurrent non-small cell lung…
-
Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development
•
Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800 million (USD 110 million) in its latest financing round. The investment was led by BridgeOne Capital and Lenovo Capital, with participation from existing investors Tsing Song Capital, Meituan LONG-Z, Qiming Venture Partners, Lilly Asia Ventures,…
-
Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its injectable DR30206, a Category 1 biologic product, in the treatment of advanced solid tumors. DR30206: A Promising Antibody Fusion Protein Targeting PD-L1,…
-
NHSA Unveils 2023 Work Plan for National Reimbursement Drug List Update
•
The National Healthcare Security Administration (NHSA) has released the “Work Plan for the National Reimbursement Drug List (NRDL) Update, 2023”, following an earlier draft proposal for this year’s NRDL update. The document contains no significant surprises and aligns with the rules used for the 2022 update. Eligibility and Update Rules…
-
Sinocelltech Group Receives NMPA Approval for COVID-19 Vaccine Bridging Phase II Study
•
China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a bridging Phase II clinical study. The study will assess the safety and immunogenicity of SCTV01E-2, an S trimer protein vaccine developed to combat COVID-19. This vaccine is designed for individuals…
-
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase III Studies of Gallium Edotreotide Injection
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with Phase III clinical studies for its gallium [68Ga] edotreotide injection and gallium [68Ga] edotreotide injection preparation kit. Gallium [68Ga]…
-
Jacobio Pharma Reports Promising Clinical Results for KRAS G12C Inhibitor Gecirasib in CRC
•
China-based Jacobio Pharma (HKG: 1167) has announced clinical results for its novel KRAS G12C inhibitor, glecirasib, in the treatment of KRAS G12C mutant advanced colorectal cancer (CRC). The findings were presented at the Second JCA-AACR Precision Medicine International Conference, showcasing the potential of glecirasib as both a monotherapy and in…
-
Harbour BioMed’s Batoclimab for Generalized Myasthenia Gravis Accepted for NMPA Review
•
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands, and Suzhou, China, has announced that the National Medical Products Administration (NMPA) has accepted a biological license application for its batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG). This development follows the positive…
